secwatch.observer — SEC 8-K summary
======================================

Issuer:     INOVIO PHARMACEUTICALS, INC. (INO)
CIK:        0001055726
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001055726-24-000053
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inovio Q3 net loss $25.2M; INO-3107 BLA on track for mid-2025 submission
------------------------------------------------------------------------

- Net loss of $25.2M ($0.89/share) vs $33.9M loss in Q3 2023; R&D expense $18.7M, G&A $8.6M.
- Cash, equivalents and short-term investments $84.8M at Sept 30, 2024; cash runway into Q3 2025.
- INO-3107 Phase 1/2 data: 81% of 32 patients had fewer surgeries; 28% had zero surgeries post-treatment.
- All non-device BLA modules for INO-3107 on track for completion by year-end 2024; BLA submission targeted mid-2025.
- Advancing Phase 3 plan for INO-3112 in HPV+ throat cancer; Phase 2 Ebola vaccine booster trial in FDA discussions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1055726/000105572624000053/0001055726-24-000053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1055726/000105572624000053/ino-20241114.htm
  HTML page:      https://secwatch.observer/filing/0001055726-24-000053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer